Trinity Biotech PLC TRIB.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended December 31. The lone analyst forecast for the quarter was for a loss of 30 cents per share.
Revenue rose 18.1% to $15.86 million from a year ago; analysts expected $16.50 million.
Trinity Biotech PLC's reported EPS for the quarter was a loss of $1.28.
The company reported a quarterly loss of $16.96 million.
Trinity Biotech PLC shares had risen by 40.4% this quarter and lost 9.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
This summary was machine generated from LSEG data May 15 at 09:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2024 | -0.30 | -1.14 | Missed |
Sep. 30 2024 | -0.54 | -0.46 | Beat |
Jun. 30 2024 | -0.65 | -0.71 | Missed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.